Knowledge-based compact disease models identify new molecular players contributing to early-stage Alzheimer’s disease

BMC Systems Biology

Ancha Baranova²  Anatoly Mayburd¹ 

[1] The Center of the Study of Chronic Metabolic Diseases, School of Systems Biology, College of Science, George Mason University, Fairfax, VA 22030, USA;Research Centre for Medical Genetics, RAMS, Moskvorechie 1, Moscow, Russia

关键词: Antihypertensive drugs;    Illumina;    Affymetrix;    Protein traffic vesicles;    Alzheimer’s;    Knowledge-based algorithms;    Network;    Signature;   

Others  :  1141818
DOI  :  10.1186/1752-0509-7-121

 received in 2013-03-06, accepted in 2013-10-28,  发布年份 2013

【 摘 要 】

Background

High-throughput profiling of human tissues typically yield as results the gene lists comprised of a mix of relevant molecular entities with multiple false positives that obstruct the translation of such results into mechanistic hypotheses. From general probabilistic considerations, gene lists distilled for the mechanistically relevant components can be far more useful for subsequent experimental design or data interpretation.

Results

The input candidate gene lists were processed into different tiers of evidence consistency established by enrichment analysis across subsets of the same experiments and across different experiments and platforms. The cut-offs were established empirically through ontological and semantic enrichment; resultant shortened gene list was re-expanded by Ingenuity Pathway Assistant tool. The resulting sub-networks provided the basis for generating mechanistic hypotheses that were partially validated by literature search. This approach differs from previous consistency-based studies in that the cut-off on the Receiver Operating Characteristic of the true-false separation process is optimized by flexible selection of the consistency building procedure. The gene list distilled by this analytic technique and its network representation were termed Compact Disease Model (CDM). Here we present the CDM signature for the study of early-stage Alzheimer’s disease. The integrated analysis of this gene signature allowed us to identify the protein traffic vesicles as prominent players in the pathogenesis of Alzheimer’s. Considering the distances and complexity of protein trafficking in neurons, it is plausible that spontaneous protein misfolding along with a shortage of growth stimulation result in neurodegeneration. Several potentially overlapping scenarios of early-stage Alzheimer pathogenesis have been discussed, with an emphasis on the protective effects of AT-1 mediated antihypertensive response on cytoskeleton remodeling, along with neuronal activation of oncogenes, luteinizing hormone signaling and insulin-related growth regulation, forming a pleiotropic model of its early stages. Alignment with emerging literature confirmed many predictions derived from early-stage Alzheimer’s disease’ CDM.

Conclusions

A flexible approach for high-throughput data analysis, the Compact Disease Model generation, allows extraction of meaningful, mechanism-centered gene sets compatible with instant translation of the results into testable hypotheses.

【 授权许可】

   
2013 Mayburd and Baranova; licensee BioMed Central Ltd.

【 图 表 】

Figure 7.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Los-Angeles T: Soaring cost of Healthcare Sets a Record. 2010. http://articles.latimes.com/2010/feb/04/nation/la-na-healthcare4-2010feb04 webcite
• [2]Huffington Post: A Look at Alzheimer’s Health Cost. 2012. http://www.huffingtonpost.com/2012/03/08/alzheimers-cost-health-medicare-expensive_n_1328986.html webcite
• [3]Feldman BM, Pai M, Rivard GE, Israels S, Poon MC, Association of Hemophilia Clinic Directors of Canada Prophylaxis Study Group, et al.: Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006, 4(6):1228-1236.
• [4]Mayburd AL, Golovchikova I, Mulshine JL: Successful anti-cancer drug targets able to pass FDA review demonstrate the identifiable signature distinct from the signatures of random genes and initially proposed targets. Bioinformatics 2008, 24(3):389-395.
• [5]Hu J, Hagler A: Chemoinformatics and Drug Discovery. Molecule 2002, 7:566-600.
• [6]Lim Hwa A: Bioinformatics and Cheminformatics in the Drug Discovery Cycle. In Lecture Notes in Computer Science 1278, Bioinformatics. Edited by Ralf H, Thomas L, Markus L, Dietmer S. Berlin: Springer-Verlag; 1997:30-43.
• [7]Sambamurti K, Jagannatha Rao KS, Pappolla MA: Frontiers in the pathogenesis of Alzheimer’s disease. Indian J Psychiatry 2009, 51(Suppl 1):S56-S60.
• [8]GeneCards Database. 2012. http://www.genecards.org/index.php?path=/Search/keyword/Alzheimer%27s webcite
• [9]Ramsköld D, Wang ET, Burge CB, Sandberg R: An abundance of ubiquitously expressed genes revealed by tissue transcriptome sequence data. PLoS Comput Biol 2009, 5(12):e1000598.
• [10]Mason R, Gunst R, Hess J: Statistical Design and Analysis of Experiments: With Applications to Engineering and Science. Volume 474. 2nd edition. Hoboken, NJ: John Wiley & Sons; 2003:760. [Wiley Series in Probability and Statistics - Applied Probability and Statistics Section Series]
• [11]Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, et al.: Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A 2004, 101:9309-9314.
• [12]Xu L, Geman D, Winslow RL: Large-scale integration of cancer microarray data identifies a robust common cancer signature. BMC Bioinformatics 2007, 8:275. BioMed Central Full Text
• [13]Tsoi LC, Qin T, Slate EH, Zheng WJ: Consistent Differential Expression Pattern (CDEP) on microarray to identify genes related to metastatic behavior. BMC Bioinformatics 2011, 2(1):438.
• [14]Mayburd AL: Expression variation: its relevance to emergence of chronic disease and to therapy. PLoS One 2009, 4(6):e5921.
• [15]Glinsky GV, Berezovska O, Glinskii AB: Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005, 115(6):1503-1521.
• [16]Liu Y, Koyutürk M, Maxwell S, Zhao Z, Chance MR: Integrative analysis of common neurodegenerative diseases using gene association, interaction networks and mRNA expression data. AMIA Summits Transl Sci Proc 2012, 2012:62-71.
• [17]Barrenas F, Chavali S, Holme P, Mobini R, Benson M: Network properties of complex human disease genes identified through genome-wide association studies. PLoS One 2009, 4(11):e8090.
• [18]Ochs MF: Knowledge-based data analysis comes of age. Brief Bioinform 2010, 11(1):30-39.
• [19]Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, et al.: Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010, 340:b5465.
• [20]Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM: Associations of anti-hypertensive treatments with Alzheimer’s disease, vascular dementia, and other dementias. Alzheimer’s Dis 2011, 26(4):699-708.
• [21]Shah K, Qureshi SU, Johnson M, Parikh N, Schulz PE, et al.: Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. Am J Geriatr Pharmacother 2009, 7(5):250-261.
• [22]Wagner G, Icks A, Abholz HH, Schröder-Bernhardi D, Rathmann W, et al.: Antihypertensive treatment and risk of dementia: a retrospective database study. Int J Clin Pharmacol Ther 2012, 50(3):195-201.
• [23]Sun J, Feng X, Liang D, Duan Y, Lei H: Down-regulation of energy metabolism in Alzheimer’s disease is a protective response of neurons to the microenvironment. J Alzheimers Dis 2012, 28(2):389-402.
• [24]Mayburd AL: Expression variation: its relevance to emergence of chronic disease and to therapy. PLoS One 2009, 4(6):e5921.
• [25]Kafri R, Dahan O, Levy J, Pilpel Y: Preferential protection of protein interaction network hubs in yeast: evolved functionality of genetic redundancy. Proc Natl Acad Sci U S A 2008, 105(4):1243-1248.
• [26]Kitano H: Biological robustness. Nat Rev Genet 2004, 5(11):826-837.
• [27]Albert R, DasGupta B, Hegde R, Sivanathan GS, Gitter A, et al.: Computationally efficient measure of topological redundancy of biological and social networks. Phys Rev E Stat Nonlin Soft Matter Phys 2011, 84(3 Pt 2):036117.
• [28]Merico D, Isserlin R, Stueker O, Emili A, Bader GD: Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One 2010, 5(11):e13984.
• [29]Bartl J, Meyer A, Brendler S, Riederer P, Grünblatt E: Different effects of soluble and aggregated amyloid β(42) on gene/protein expression and enzyme activity involved in insulin and APP pathways. J Neural Transm 2013, 120(1):113-120.
• [30]Zhang TL, Fu JL, Geng Z, Yang JJ, Sun XJ: The neuroprotective effect of losartan through inhibiting AT1/ASK1/MKK4/JNK3 pathway following cerebral I/R in rat hippocampal CA1 region. CNS Neurosci Ther 2012, 18(12):981-987.
• [31]Palkovits M, Šebeková K, Klenovics KS, Kebis A, Fazeli G, Bahner U, Heidland A: Neuronal activation in the central nervous system of rats in the initial stage of chronic kidney disease-modulatory effects of losartan and moxonidine. PLoS One 2013, 8(6):e66543.
• [32]Hashikawa-Hobara N, Hashikawa N, Inoue Y, Sanda H, Zamami Y, Takatori S, Kawasaki H: Candesartan cilexetil improves angiotensin II type 2 receptor-mediated neurite outgrowth via the PI3K-Akt pathway in fructose-induced insulin-resistant rats. Diabetes 2012, 61(4):925-932.
• [33]Mitra AK, Gao L, Zucker IH: Angiotensin II-induced upregulation of AT(1) receptor expression: sequential activation of NF-kappaB and Elk-1 in neurons. Am J Physiol Cell Physiol 2010, 299(3):C561-C569.
• [34]Moreno AS, Franci CR: Estrogen modulates the action of nitric oxide in the medial preoptic area on luteinizing hormone and prolactin secretion. Life Sci 2004, 74(16):2049-2059.
• [35]Harada N, Shimozawa N, Okajima K: AT(1) receptor blockers increase insulin-like growth factor-I production by stimulating sensory neurons in spontaneously hypertensive rats. Transl Res 2009, 154(3):142-152.
• [36]Miyamoto N, Zhang N, Tanaka R, Liu M, Hattori N, et al.: Neuroprotective role of angiotensin II type 2 receptor after transient focal ischemia in mice brain. Neurosci Res 2011, 61(3):249-256.
• [37]Kiyota T, Ingraham KL, Jacobsen MT, Xiong H, Ikezu T: FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer’s disease and has therapeutic implications for neurocognitive disorders. Proc Natl Acad Sci U S A 2011, 108(49):E1339-E1348.
• [38]Webber KM, Casadesus G, Bowen RL, Perry G, Smith MA: Evidence for the role of luteinizing hormone in Alzheimer disease. Endocr Metab Immune Disord Drug Targets 2007, 7(4):300-303.
• [39]Stroth U, Meffert S, Gallinat S, Unger T: Angiotensin II and NGF differentially influence microtubule proteins in PC12W cells: role of the AT2 receptor. Brain Res Mol Brain Res 1998, 53(1–2):187-195.
• [40]Laflamme L, Gasparo M, Gallo JM, Payet MD, Gallo-Payet N: Angiotensin II induction of neurite outgrowth by AT2 receptors in NG108-15 cells. Effect counteracted by the AT1 receptors. J Biol Chem 1996, 271(37):22729-22735.
• [41]Govindarajan G, Eble DM, Lucchesi PA, Samarel AM: Focal adhesion kinase is involved in angiotensin II-mediated protein synthesis in cultured vascular smooth muscle cells. Circ Res 2000, 87(8):710-716.
• [42]Hercule HC, Tank J, Plehm R, Wellner M, da Costa Goncalves AC, et al.: Regulator of G protein signalling 2 ameliorates angiotensin II-induced hypertension in mice. Exp Physiol 2007, 92(6):1014-1022.
• [43]Heximer SP, Knutsen RH, Sun X, Kaltenbronn KM, Rhee MH, et al.: Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice. J Clin Invest 2003, 111(4):445-452.
• [44]Matsuzaki N, Nishiyama M, Song D, Moroi K, Kimura S: Potent and selective inhibition of angiotensin AT1 receptor signaling by RGS2: roles of its N-terminal domain. Cell Signal 2011, 23(6):1041-1049.
• [45]Fujio Y: RGS2 determines the preventive effects of ARBs against vascular remodeling: toward personalized medicine of anti-hypertensive therapy with ARBs. Hypertens Res 2010, 33(12):1221-1222.
• [46]Mitchell A, Rushentsova U, Siffert W, Philipp T, Wenzel RR: The angiotensin II receptor antagonist valsartan inhibits endothelin 1-induced vasoconstriction in the skin microcirculation in humans in vivo: influence of the G-protein beta3 subunit (GNB3) C825T polymorphism. Clin Pharmacol Ther 2006, 79(3):274-281.
• [47]Chang JW, Wei NC, Su HJ, Huang JL, Chen TC, et al.: Comparison of genomic signatures of non-small cell lung cancer recurrence between two microarray platforms. Anticancer Res 2012, 32(4):1259-1265.
• [48]Kresse SH, Szuhai K, Barragan-Polania AH, Rydbeck H, Cleton-Jansen AM, et al.: Evaluation of high-resolution microarray platforms for genomic profiling of bone tumours. BMC Res Notes 2010, 3:223. BioMed Central Full Text
• [49]Verdile G, Laws SM, Henley D, Ames D, Bush AI, et al.: Associations between gonadotropins, testosterone and β amyloid in men at risk of Alzheimer’s disease. Mol Psychiatry 2012. 10.1038/mp.2012.147
• [50]Hyde Z, Flicker L, Almeida OP, McCaul KA, Jamrozik K, et al.: Higher luteinizing hormone is associated with poor memory recall: the health in men study. J Alzheimers Dis 2010, 19(3):943-951.
• [51]Chu C, Zhou J, Zhao Y, Liu C, Chang P, et al.: Expression of FSH and its co-localization with FSH receptor and GnRH receptor in rat cerebellar cortex. J Mol Histol 2012, 44(1):19-26.
• [52]Casadesus G, Atwood CS, Zhu X, Hartzler AW, Webber KM, et al.: Evidence for the role of gonadotropin hormones in the development of Alzheimer disease. Cell Mol Life Sci 2005, 62(3):293-298.
• [53]Karlsson AB, Maizels ET, Flynn MP, Jones JC, Shelden EA, et al.: Luteinizing hormone receptor-stimulated progesterone production by preovulatory granulosa cells requires protein kinase A-dependent activation/dephosphorylation of the actin dynamizing protein cofilin. MolEndocrinol 2010, 24(9):1765-1781.
• [54]Nicholls PK, Harrison CA, Walton KL, McLachlan RI, O’Donnell L, et al.: Hormonal regulation of sertoli cell micro-RNAs at spermiation. Endocrinology 2011, 152(4):1670-1683.
• [55]Pantic I, Basta-Jovanovic G, Starcevic V, Paunovic J, Suzic S, et al.: Complexity reduction of chromatin architecture in macula densa cells during mouse postnatal development. Nephrology (Carlton) 2013, 18(2):117-124.
• [56]King GD, Rosene DL, Abraham CR: Promoter methylation and age-related downregulation of Klotho in rhesus monkey. Age (Dordr) 2012, 34(6):1405-1419.
• [57]Klein CJ, Botuyan MV, Wu Y, Ward CJ, Nicholson GA, et al.: Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss. Nat Genet 2011, 43(6):595-600.
• [58]Pietrzak M, Rempala G, Nelson PT, Zheng JJ, Hetman M: Epigenetic silencing of nucleolar rRNA genes in Alzheimer’s disease. PLoS One 2011, 6(7):e22585.
• [59]Johnson AA, Akman K, Calimport SR, Wuttke D, Stolzing A, et al.: The role of DNA methylation in aging, rejuvenation, and age-related disease. Rejuvenation Res 2012, 15(5):483-494.
• [60]Yoon HE, Ghee JY, Piao S, Song JH, Han DH, et al.: Angiotensin II blockade upregulates the expression of Klotho, the anti-ageing gene, in an experimental model of chronic cyclosporine nephropathy. Nephrol Dial Transplant 2011, 26(3):800-813.
• [61]Chu CH, Lo JF, Hu WS, Lu RB, Chang MH, et al.: Histone acetylation is essential for ANG-II-induced IGF-IIR gene expression in H9c2 cardiomyoblast cells and pathologically hypertensive rat heart. J Cell Physiol 2012, 227(1):259-268.
• [62]Sanchez-Varo R, Trujillo-Estrada L, Sanchez-Mejias E, Torres M, Baglietto-Vargas D, Moreno-Gonzalez I, De Castro V, Jimenez S, Ruano D, Vizuete M, Davila JC, Garcia-Verdugo JM, Jimenez AJ, Vitorica J, Gutierrez A: Abnormal accumulation of autophagic vesicles correlates with axonal and synaptic pathology in young Alzheimer’s mice hippocampus. Acta Neuropathol 2012, 123(1):53-70.
• [63]Gunawardena S, Yang G, Goldstein LS: Presenilin controls kinesin-1 and dynein function during APP-vesicle transport in vivo. Hum Mol Genet 2013, 22(19):3828-3843.
• [64]Driver JA, Beiser A, Au R, Kreger BE, Splansky GL, Kurth T, Kiel DP, Lu KP, Seshadri S, Wolf PA: Inverse association between cancer and Alzheimer’s disease: results from the Framingham Heart Study. BMJ 2012, 344:e1442.
• [65]Keeney JT, Swomley AM, Harris JL, Fiorini A, Mitov MI, Perluigi M, Sultana R, Butterfield DA: Cell cycle proteins in brain in mild cognitive impairment: insights into progression to Alzheimer disease. Neurotoxicity Research 2012, 22(3):220-230.
• [66]Sieradzki A, Yendluri BB, Palacios HH, Parvathaneni K, Reddy VP, Obrenovich ME, Gąsiorowski K, Leszek J, Aliev G: Implication of Oncogenic Signaling Pathways as a Treatment Strategy for Neurodegenerative Disorders-Contemporary Approaches. CNS Neurol Disord Drug Targets 2011, 10(2):175-183.
• [67]Demetrius LA, Simon DK: The inverse association of cancer and Alzheimer’s: a bioenergetic mechanism. J R Soc Interface 2013, 10(82):20130006.
• [68]Eckert GP, Renner K, Eckert SH, Eckmann J, Hagl S, Abdel-Kader RM, Kurz C, Leuner K, Muller WE: Mitochondrial dysfunction–a pharmacological target in Alzheimer’s disease. Mol Neurobiol 2012, 46(1):136-150.
• [69]Bowen RL, Smith MA, Harris PL, Kubat Z, Martins RN, Castellani RJ, Perry G, Atwood CS: Elevated luteinizing hormone expression colocalizes with neurons vulnerable to Alzheimer’s disease pathology. J Neurosci Res 2002, 70:514-518.